CIITA
CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more.
Overview
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984,.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.00, somatic mutation 0.83). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more.
- 1 · What it is
CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more.
- 2 · What goes wrong in cancer
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA.
- 3 · How drugs use it
No product in this corpus aims at CIITA yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:7067 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P33076 (protein name, function text, keywords and locations (REST API)); CIViC gene CIITA (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000179583 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: colorectal cancer 0.52, melanoma 0.56, non-Hodgkin lymphoma 0.50, skin cancer 0.55, lung cancer 0.51 (GraphQL API, CC0)); IntOGen CIITA (driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984,. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter. Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Activates CD74 transcription. Location: Nucleus; Nucleus, PML body (UniProt). Locus 16p13.13 (HGNC).
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Non-Hodgkin lymphoma: Open Targets association 0.50 with non-Hodgkin lymphoma (MONDO_0018908)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CIITA" OR ABSTRACT:"CIITA" OR TITLE:"class II major histocompatibility complex transactivator" OR ABSTRACT:"class II major histocompatibility complex transactivator" OR TITLE:"MHC class II transactivator" OR ABSTRACT:"MHC class II transactivator" OR TITLE:"C2TA" OR ABSTRACT:"C2TA" OR TITLE:"MHC2TA" OR ABSTRACT:"MHC2TA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIITA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetBCL6
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetTNFRSF14
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetB2M
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetPOU2AF1
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCDX2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetEBF1
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.